Pepto-Bismol — undated, occurred to me at a drug store
So Pepto-Bismol started life in 1901 as an emergency cholera infantum remedy mixed up in a New York doctor's office, sold in bulk to other physicians, and called — until somebody at the marketing department realized this was a bad name for a consumer product — Bismosal: Mixture Cholera Infantum, which is to say, the original branding was the name of the disease it was supposed to treat in babies, who were in fact dying of it in industrial-scale numbers in American cities in 1901 because nobody had figured out pasteurization yet and infants drinking summer milk in a tenement were essentially playing Russian roulette with their own gut flora.
The standard story credits an unnamed physician working in New York and the formulation gets picked up commercially by Norwich Pharmacal Company in upstate New York, which spent the first half of the 20th century being the company that owned Pepto-Bismol and not much else of consequence. Norwich, the town, is sort of the pharmaceutical-industrial equivalent of one of those Saxon silver towns from the Agricola era — small place, one main product, a labor force trained specifically in the one thing that pays the bills there, and a downstream effect on local culture and architecture and prosperity that you can still see if you drive through the place in 2026, even though the company itself got absorbed into Procter & Gamble's portfolio in the 1980s and the pink-bottling operation moved away long ago.
The active ingredient is bismuth subsalicylate, which is two molecules doing two completely different jobs in your stomach simultaneously, and the genius of the formulation — to the extent there is one — is that the two jobs happen to be the two jobs you most need done when you're standing in a hotel bathroom in Cancun at three in the morning regretting the ceviche.
Bismuth is the heavy metal. (Heavy metal in the chemistry sense, atomic number 83, sitting right next to lead and polonium on the periodic table, although weirdly nontoxic in a way its neighbors very much aren't — bismuth is the heaviest stable element, sort of the friendly uncle of the dangerous part of the periodic table.) The subsalicylate is the salicylate, which is the same family of compounds aspirin belongs to, doing the anti-inflammatory and mildly antibacterial work. Together they coat the stomach lining and slow down everything in your GI tract by varying mechanisms that researchers were still publishing papers about as recently as the 2010s — the molecule has been in widespread use for 120 years and we are still working out exactly why it does the thing it does.
An absolutely arbitrary aesthetic choice somebody at Norwich made in I think the 1920s, sticking with the kind of cake-frosting Pepto-pink that became so identified with the product that if you mix up a pure bismuth subsalicylate solution in a lab today, the natural color is sort of pale chalky white, which would not move units, hence the dye, hence the bottle, hence eighty years of children associating the color pink with stomachache relief in what has to be one of the more successful color-coded conditioning programs in the history of American consumer goods.
The bismuth itself is a story all by itself. Bismuth has historically been a byproduct metal — you don't mine bismuth, you mine for lead or copper or tin and you separate the bismuth out at the smelter, because bismuth occurs in the same ore bodies as those more economically important metals and is essentially what's left over after you've extracted the parts you actually wanted. The historic centers of bismuth production were the same Erzgebirge and Saxon mining districts where Agricola was working in the 1550s, because the silver-lead-copper polymetallic deposits of Central Europe happen to also be where the bismuth concentrates. The 20th century moved production around — Peru, Bolivia, Mexico — but in the current moment something like 80% of the world's bismuth supply comes out of China, almost all of it as a smelter byproduct from lead refining at facilities in Hunan and Jiangxi, which means the pink bottle on the shelf at your CVS is in some causal sense connected to lead-mining decisions made by Chinese state-owned enterprises and to environmental regulations in the lead-smelting business, neither of which has anything to do with what Pepto-Bismol is for.
Lead refining produces bismuth as a side effect. Bismuth subsalicylate quiets the runs. The supply chain runs from a tailings pond in Hunan to a tourist bathroom in Cancun, through a P&G plant in either Greensboro or Cincinnati depending on the year, and the price of your trip is partly set by Chinese lead policy.
You don't think about this. Nobody does.
(The Chinese near-monopoly is a recent thing — the U.S. Defense Logistics Agency used to maintain a strategic bismuth stockpile, because bismuth is also used in some specialty alloys and as a lead substitute in plumbing fixtures and shotgun pellets, and the Cold War theory was that if the lead-bismuth supply got disrupted you didn't want to be caught short. The stockpile got sold off in the 1990s on the theory that the global market had matured, which it had, except the global market then consolidated in one country, which is the thing global markets do whenever Western planners declare them mature.)
The salicylate side has its own arc. Salicylic acid, the parent compound, comes from willow bark — the Hippocratic tradition knew about willow bark as a fever reducer, German chemists isolated the active compound in the 19th century, Bayer turned it into aspirin in 1899, and the salicylate molecule then proliferated through 20th-century pharmacy as a base for a whole family of derivatives. Bismuth subsalicylate is one such derivative. The pairing of a heavy metal with a salicylate was the kind of thing turn-of-the-century pharmacists did all the time, throwing combinations against the wall to see what stuck, and most of those combinations got dropped within a decade. Pepto stuck because babies in 1901 actually stopped dying when they took it, which is the highest bar a product can clear.
Then a generation went by and the babies weren't dying anymore — pasteurization happened, milk supplies got cleaner, sanitation in cities improved, and the original use case essentially evaporated. Cholera infantum stopped being a leading cause of infant death in the United States. The Mixture Cholera Infantum was a remedy for a condition that no longer existed at scale.
A lesser product would have died with its disease.
What happened instead is what happens to a lot of products that survive the disappearance of their original problem — Norwich rebranded it, repositioned it, found a new use case, pushed it from the pediatric infant-mortality market into the adult upset-stomach market, which is a much bigger market and one that, crucially, will never go away, because every culture in the world produces foods that some fraction of the population can't digest and humans are going to keep eating the wrong thing at the wrong time until the species ends. By the 1940s Pepto-Bismol was an adult OTC product. The original use was vestigial — written on the label in tiny print, then gradually removed, until by the 1970s nobody under sixty remembered what the product had been for in the first place.
(There's a Reye's syndrome warning on the bottle now, precisely because the salicylate component shouldn't be given to children under twelve with viral infections, which means the product that was invented to save babies is now contraindicated for children. The pharmacology hasn't changed. The information about salicylates and viral encephalopathy has. The product survived by changing who it was for, three different ways across three different decades.)
And then in the 1980s Barry Marshall and Robin Warren in Australia worked out that stomach ulcers were caused by a bacterium, Helicobacter pylori, a finding so heretical to the gastroenterology consensus of the day that Marshall had to drink a beaker of H. pylori culture himself, develop gastritis, and then cure himself, in order to get anyone to take the work seriously. They got the Nobel for it in 2005. And it turned out that one of the few cheap, readily available, over-the-counter compounds with actual bactericidal activity against H. pylori — antibiotics are the primary treatment, but as part of the quadruple-therapy regimens — is bismuth subsalicylate. The pink stuff. The cake-frosting-colored chalky pediatric remedy from 1901, originally aimed at a bacterial infection (the cholera-adjacent bacteria killing babies on summer milk) and then sold for fifty years as a non-specific stomach-soother, turned out to be doing actual antibacterial work against an actual specific bacterium all along, which the science only caught up to in the 21st century.
This is the thing about long-tailed consumer pharmaceuticals — the ones that survive a hundred years are usually surviving because the underlying biochemistry turns out to do more than the original formulators understood, and the formulators got it on the shelf for one reason and the molecule keeps earning its shelf space for completely different reasons that get discovered decade by decade. Aspirin is the canonical example (heart-attack prevention was a 1970s discovery, four generations after the molecule went on sale). Pepto is the second-tier version of the same story.
The travel-diarrhea use case, which is most Americans' actual encounter with the product, is downstream of the postwar tourism boom, GIs coming back from the Pacific and Mediterranean theaters with chronic gut problems, the airline industry making intercontinental leisure travel a middle-class experience by the 1960s, and the discovery — by trial and error among American tourists in Mexico and India and Egypt — that the pink stuff worked. There were studies in the 1970s and 1980s that put numbers on the prophylactic effect, and for a while the medical guidance was actually that travelers should take Pepto preventively, which turned out to be a bad idea if you were doing it for weeks at a time because the bismuth accumulates and your tongue turns black, but that's a separate story.
(The black tongue thing, and the black stool, are bismuth sulfide — your gut bacteria react the bismuth with sulfur compounds in the digestive tract and you produce a thin layer of the same metal sulfide that occurs as a black crust on weathered bismuth ore. Your mouth becomes briefly a smelter. The mineralogy of bismuth is reenacting itself inside you.)
What I keep coming back to is the supply chain. The pink chalk in the bottle is, as a matter of physical history, a chunk of central Chinese lead-smelting byproduct combined with a derivative of willow-bark chemistry that was industrialized in Germany around the time of the Boer War, mixed with food-grade pink dye whose color was chosen by a marketing department in upstate New York during the Coolidge administration, and sold to you for the purpose of treating a condition that the original formulation was not designed for and whose underlying mechanism only got fully described in the mid-2000s. Each component of the product comes from a different century and a different country and a different industry, and the whole thing costs $7.99 at Walgreens.
The product survives because the molecule is interesting and the molecule is interesting because three or four unrelated chemistries happen to converge in it, and consumer pharmacy is mostly the business of finding such molecules and then attaching them to whatever market is currently the largest. The cholera babies died off. The tourists arrived. The ulcer patients showed up. The molecule kept earning its keep through three different epidemiological eras by being three different things, and the bottle, the color, the chalky taste, those have stayed roughly the same since the dye choice in the 1920s, because the consumer relationship to the product is essentially nostalgic at this point. People reach for the pink because their parents reached for the pink. The pharmacology underneath the nostalgia is a moving target. The pink is the constant.